Monday Aug 18
Pharmacyclics Appoints Chief Commercial Officer
Pharmacyclics, Inc. today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer.
Sun Aug 17, 2014
Pharmacyclics Given Consensus Rating of "Buy" by Analysts
Pharmacyclics has earned an average recommendation of "Buy" from the nineteen analysts that are currently covering the company, American Banking & Market News reports .
Thu Aug 14, 2014
Biotech Leads the Way
You will receive a download link right in your email inbox for each of the free reports that you choose.
Wed Aug 13, 2014
Pharmacyclics Has Edge Over Blood Cancer Competitors
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Pharmacyclics Receives Average Recommendation of "Buy" from Brokerages
Pharmacyclics has received an average rating of "Buy" from the nineteen ratings firms that are covering the stock, Analyst Ratings Network.com reports .
Fri Aug 08, 2014
Pharmacyclics Trading Down 3.5% After Insider Selling
Pharmacyclics was down 3.5% during trading on Friday after an insider sold shares in the company, American Banking News reports.
Pharmacyclics Inc - 10-Q - Management's Discussion and Analysis of...
You should read the following discussion and analysis of our financial condition and results of operations together with our interim financial statements and the related notes appearing at the beginning of this report.
Tue Aug 05, 2014
Pharmacyclics Price Target Raised to $180.00 at William Blair
The firm currently has an "outperform" rating on the stock. William Blair's price objective suggests a potential upside of 51.18% from the stock's previous close.
Sat Aug 02, 2014
Pharmacyclics Rating Reiterated by Zacks
's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Friday.
Fri Aug 01, 2014
The Best Blood Cancer Drug Launch Ever?
Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets.
Thu Jul 31, 2014
Pharmacyclics Reports Second Quarter 2014 Results
Pharmacyclics, Inc. today reported financial results and recent developments for the quarter ended June 30, 2014.
Tue Jul 29, 2014
Stocks On the Move: Corning Incorporated, Oshkosh Corporation, and Pharmacyclics, Inc.
U.S. stocks are marginally higher this afternoon, with solid gains for DuPont and Merck & Co., Inc. propping up the Dow.
Mon Jul 28, 2014
Pharmacyclics Announces Date of Conference call to discuss Financial...
Pharmacyclics, Inc. today announced that it will hold a conference call and audio webcast to discuss financial results for the second quarter of 2014 after the NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 p.m. ET.
In Europe, two drugs will compete to treat rare blood cancer
In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.
U.S. FDA Grants Regular (Full) Approval For Pharmacyclics, Inc.'s...
This is the first full FDA approval for IMBRUVICA, and was granted within six months after the accelerated approval for patients with previously treated CLL in February 2014.
Fri Jul 25, 2014
EMA recommends full marketing approval for IMBRUVICA in the European Union
Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA in the European Union.
Thu Jul 24, 2014
Profits and capacity utilisation up at Lonza in H1 thanks to pharma
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
Biomedical engineer looks at new applications for novel lupus drug
Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.
Wed Jul 23, 2014
The Motley Fool
Is Gilead About to Crush Pharmacyclics Stock?
However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.
Pharmacyclics estimates raised ahead of Q2 report at Goldman
Pharmacyclics estimates raised ahead of Q2 report at Goldman Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data.